Thanks to homegrown talent, A-list investors, and new owner Willow Bay, the women’s soccer team has won the industry’s hearts ...

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.

Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful Phase 3 study.

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite affordability, supply capacity, and growing demand in the U.S. market.

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive.

External Affairs Minister S Jaishankar is on a three-day visit to Moscow, where he met with Russian President Vladimir Putin.

Escalation of doses of biologic therapies in IBD may be key to improve patient care, showing a good response rate and ...

Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 agonists for diabetes, with new data for Mounjaro on cardiovascular outcomes.